Register for our free email digests:
Latest From Applied Therapeutics Inc.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in January and February 2017.
Finance Watch: Surrozen Raises $33m In $483m February Flurry; Also, Are Reverse Mergers This Year's IPOs?
Surrozen raised $33m to fund drug development programs targeting Wnt ligands for various indications during a February VC financing flurry that occurred despite a drop in IPOs. Taking an alternative route to going public, some biopharma companies have completed reverse mergers in recent weeks and months.
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- North America
- Parent & Subsidiaries
- Cytokinetics Inc.
- Senior Management
Robert I Blum, Pres. & CEO
Sharon Barbari, EVP, Fin. & CFO
Andrew A Wolff, MD, SVP, CMO
Elisabeth A Schnieders, PhD, SVP, Bus. Dev.
Scott R Jordan, VP, Commercial Dev.
- Contact Info
Phone: (650) 624-3000
280 East Grand Ave.
S. San Francisco, CA 94080
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.